Are you ready to heal the failing heart and rescue its beat? PERM1, a promising protein, paves the way for new treatments for systolic heart failure. The heart, an extraordinary muscle, beats ...
Heart failure sounds alarming—and rightfully so. Yet approximately 6.5 million Americans currently live with this condition, many with the specific variant called systolic heart failure, and a ...
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA ...
Pharmaceutical Technology on MSN
Cytokinetics receives FDA approval for MYQORZO tablets for oHCM
Cytokinetics has announced that the US Food and Drug Administration (FDA) has approved MYQORZO (aficamten) tablets in 5mg, ...
FDA approved CYTK's Myqorzo for oHCM. It reduces heart's pumping ability, has a warning for heart failure and expected to ...
Through a deep-learning model, researchers have shown that ordinary ECG images can be leveraged to identify patients with an LV ejection fraction below 40%. Their approach also appears able to ...
Stocktwits on MSN
Cytokinetics wins first FDA approval for heart disease drug — why is Wall Street still cautious?
The drug is now expected to be available in the U.S. in the second half of January 2026. ・The prescribing information for the ...
Patients hospitalized for severe COVID-19 exhibit cardiac systolic dysfunction and small vessel disease at long-term follow-up. This is according to a new study from Karolinska Institutet and ...
It is a common perception that approximately 50% of heart failure (HF) patients present with a normal or near-normal left ventricular (LV) ejection fraction ("HF with preserved systolic function"), ...
Each month, The Clinical Advisor makes one new clinical feature available ahead of print. Don’t forget to take the poll. The results will be published in the next month’s issue. The American Heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback